EASL

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, May 11, 2022
Company, European Association for the Study of the Liver, Private Securities Litigation Reform Act, Research, HBV, U.S. Securities and Exchange Commission, Autoimmunity, Oxford University Innovation, Infection, Patient, Insurance, Vaccine, NASDAQ, EASL, Association, University, COVID-19, IND, Prostate cancer, EMA, Program, ChAdOx1, Licensure, OUI, Vaccitech, Immune system, MVA, MERS, Degenerative disease, SEC, Cancer, Acquisition, Security (finance), AstraZeneca, HPV, GLOBE, Pharmaceutical industry, Liver

OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Companys recent corporate developments.
  • On April 6, 2022, the Company announced the notification of the commencement of royalty payments relating to commercial sales of Vaxzevria.
  • The Companys share of milestone and royalty payments received by OUI from AstraZeneca in the first quarter of 2022 amounted to $15.0 million.
  • First Quarter 2022 Financial Highlights:
    Cash position: As of March 31, 2022, cash and cash equivalents were $200.6 million, compared to $214.1 million as of December 31, 2021.

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

Retrieved on: 
Monday, May 9, 2022
Population, Doctor's visit, NASDAQ, GLOBE, Company, NDA, Safety, EASL, Patient, Fibrosis, Histology, European Association for the Study of the Liver, Cirrhosis, Association, Clinical trial, Steatosis, Therapy, 2021 Essex County Council election, NASH, Principal, Fatty liver disease, Liver, University of Oxford, Medical imaging, Pharmaceutical industry, Madrigal, Q4

CONSHOHOCKEN, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today announced acceptance of four abstracts for oral presentation at the European Association for the Study of the Liver’s (EASL) International Liver Congress, including a late-breaker presentation of data from the Phase 3 MAESTRO-NAFLD-1 trial, as well as other resmetirom clinical development program updates. The Company also reported financial results for the first quarter of 2022, including the completion of a $250 million term loan facility to support resmetirom clinical and commercial development objectives and position Madrigal for a potential first-to-market launch in NASH. The company drew $50 million from the facility at closing and has the ability to draw a further $200 million under the agreement.

Key Points: 
  • The Company also reported financial results for the first quarter of 2022, including the completion of a $250 million term loan facility to support resmetirom clinical and commercial development objectives and position Madrigal for a potential first-to-market launch in NASH.
  • We look forward to sharing detailed MAESTRO-NAFLD-1 results in a late-breaking presentation at EASL followed by topline results from the MAESTRO-NASH biopsy study in Q4.
  • The safety and efficacy results that will be presented at EASL are supportive of a potential for benefit in this population.
  • Madrigal may also draw an additional $125 million in two separate tranches upon achievement of resmetirom clinical and regulatory milestones.

Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Investment, Hepatitis B, Assembly, Nasdaq, Degenerative disease, GLOBE, RNA, CFBV, Company, Research, EASL, HBV, Â, Patient, Coronavirus, Clinical trial, Technology transfer, Virology, RNA interference, Therapy, 2021 Essex County Council election, NA, Severe acute respiratory syndrome coronavirus 2, VBR, Roivant Sciences, Vaccine, Pharmaceutical industry, Cryptocurrency, IND, Vaccitech

WARMINSTER, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its first quarter 2022 financial results and provides pipeline updates.

Key Points: 
  • WARMINSTER, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its first quarter 2022 financial results and provides pipeline updates.
  • Additionally, we have had seven abstracts accepted at the EASL International Liver Congress, which include some of these data.
  • Report data set from the AB-836-001 clinical trial evaluating multiple doses of AB-836 in cHBV patients in the first half of 2022.
  • Advance an oral compound that inhibits the SARS-CoV-2 nsp5 main protease into IND enabling studies in the second half of 2022.

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Drug development, Hyperlipidemia, Sirna, U.S. Securities and Exchange Commission, Forward-looking statement, PF-07321332, KU Leuven, Nasdaq, Hepatitis, GLOBE, Liver disease, Merck, Probability, EASL, HBV, Institute of Liver and Biliary Sciences, Research, CTA, Patient, Security (finance), Doctor of Philosophy, Fatty liver disease, Clinical trial, Human, CHB, Therapy, Class, Face, R, Severe acute respiratory syndrome coronavirus 2, Private Securities Litigation Reform Act, Chief executive officer, HVS, ASO, NASH, MBA, Terminology, CEO, Viral hepatitis, G&A, Abstract, SAN, CAM, Degenerative disease, Pharmaceutical industry, Generic drug, Q2, Jacob Aligo, Q3

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the first quarter March 31, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the first quarter March 31, 2022.
  • We plan to share top line results for 28 day and 12-week cohorts in Q2 and Q4 2022, respectively.
  • Topline results from this Phase 1 proof of concept study remain on track for release in Q3 2022.
  • Aligos expects to file a Phase 1 clinical trial application in second half of 2022.

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, Drug development, U.S. Securities and Exchange Commission, Forward-looking statement, Nasdaq, Congress, Hepatitis, GLOBE, Â, Liver disease, Time, EASL, Institute of Liver and Biliary Sciences, Doctor of Philosophy, Patient, Security (finance), European Association for the Study of the Liver, Association, Fatty liver disease, Annual report, CHB, Therapy, 2021 Essex County Council election, Private Securities Litigation Reform Act, NASH, MBA, Terminology, Viral hepatitis, SAN, BST, Degenerative disease, Pharmaceutical industry, Book, Reinsurance, Jacob Aligo

The posters will be available subsequently on the Scientific Presentation and Publications page in the Presentations section of Aligos website at www.aligos.com .

Key Points: 
  • The posters will be available subsequently on the Scientific Presentation and Publications page in the Presentations section of Aligos website at www.aligos.com .
  • Presentation details for each abstract accepted to date are listed below.
  • By continuing to advance a diverse CHB portfolio, we aim to be able to evaluate multiple approaches to providing better outcomes for patients with CHB.
  • The conference will announce a second set of accepted abstracts before the beginning of the congress, which may include other abstracts submitted by Aligos.

Innovative New Products and Technology Advancing Worldwide Liver Disease Management Highlight Echosens 20th Anniversary

Retrieved on: 
Tuesday, December 14, 2021
Health, Medical Devices, Technology, Managed Care, General Health, Hardware, Biotechnology, Agile, SSM, NAFLD, Solution, Fatty liver disease, European Association of Urology, Physician, Diagnosis, Cirrhosis, Non-alcoholic fatty liver disease, EASL, Health, Adult, Liver disease, Association, NASH, The American Journal of Managed Care, American Journal, United, MIB, Steatosis, Chronic liver disease, National Institute, Spleen, CEO, National Institute for Health and Care Excellence, SBA, Patient, NICE, LSM, Pioneer, CAP, Publication, Elastography, Medical imaging, Medical device, Liver

In the past year alone Echosens launched three new global products all carefully designed to optimize the overall FibroScan experience.

Key Points: 
  • In the past year alone Echosens launched three new global products all carefully designed to optimize the overall FibroScan experience.
  • This device is the complete non-invasive solution for liver disease management, powered by liver stiffness measurement (LSM by VCTE) CAP and spleen stiffness measurement (SSM by VCTE) as part of an overall assessment of the liver.
  • Recently, Echosens launched FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients.
  • Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan, the non-invasive solution for comprehensive management of liver health.

Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 3, 2021
Safety, Fibrosis, Magnetic resonance imaging, EASL, Human, Hypercholesterolemia, The Obesity Society, Lipid, SAN, GIP, Disease, Adrenoleukodystrophy, Triglyceride, Obesity, X-ALD, Patient, Trial of the century, NASDAQ, AMN, Vital signs, Review, Quarter, Adult, Male, Program, Pharmacokinetics, Non-alcoholic fatty liver disease, Fatty liver disease, Therapy, NASH, Half-life, Risk, Population, Lists of diseases, Neurodegeneration, Plasma, Pharmaceutical industry

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.

Key Points: 
  • SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.
  • Viking ended the third quarter of 2021 with approximately $216 million in cash, cash equivalents and short-term investments.
  • Management will host a conference call to discuss the company's third quarter 2021 financial results today at 4:30 pm Eastern.
  • This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S.

Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer

Retrieved on: 
Tuesday, October 19, 2021
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ODD, Cirrhosis, Center, Nature Reviews Gastroenterology & Hepatology, Liposome, Association, Internal medicine, Kidney, Institute of Liver and Biliary Sciences, EASL, Mark (given name), Medical school, EMA, ETH Zurich, American Association for the Study of Liver Diseases, Adult, Inselspital, Board, Professor, Center for Molecular Neurobiology Hamburg, AASLD, Molecular biology, Associate, FDA, CEO, Brain, Patient, University, Industry, University Medical Center, Gastroenterology, COO, University Medical Center Hamburg-Eppendorf, European Association for the Study of the Liver, U.S. FDA, ACLF, American Association, Medical University of Vienna, Therapy, University of Hamburg, Trial of the century, Medical imaging, Pharmaceutical industry

Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer.

Key Points: 
  • Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer.
  • Prof Staufer is a gastroenterologist and hepatologist with a strong clinical and scientific background in metabolic liver disease, liver cirrhosis and transplant hepatology, including orphan liver diseases.
  • We look forward to the contribution that Katharina will bring to unfold the full potential of VS-01 in our key adult and pediatric indications.
  • Versantis is a clinical stage company focused on addressing the growing, un-met medical need in liver diseases.

Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update

Retrieved on: 
Thursday, September 23, 2021
Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, EUR, Goal, Type 2 diabetes, Trial, Senior, Program, POC, ILC, Scientific communication, Chronic kidney disease, Director, ALD, TIMES, Inflammation, Investor relations, JPY, Lists of diseases, Association, Public relations, Adult, NASH, CEO, European Association for the Study of the Liver, Disease, Drug development, Male, AMN, VLCFA, Conditional sentence, Fatty liver disease, United Nations Scientific Committee on the Effects of Atomic Radiation, Pharmacology, Plasma, Tablet, EASL, Exocrine gland, Corporate communication, USD, Achievement, FXR, Therapy, Degenerative disease, Adrenoleukodystrophy, R, Pharmacokinetics, Nervous system, Sumitomo Dainippon Pharma, Euronext, Annual, Patient, Metaves, Imeglimin, Biomarker, Board, AMPK, IPF, Efficacy, CKD, Pharmaceutical industry, Medical device, Management

This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.

Key Points: 
  • This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.
  • Poxel is well-positioned to leverage its existing platforms to develop therapeutics in rare metabolic diseases, Mr. Kuhn concluded.
  • In July 2021, Poxel received a milestone payment of JPY 1.75 billion (approximately EUR 13.2 million, USD 15.8 million)1 from Sumitomo Dainippon Pharma.
  • Revenue for the first half of 2021 mostly reflects the JPY 1.75 billion (EUR 13.2 million) milestone payment from Sumitomo Dainippon Pharma which Poxel received in July 2021.

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Retrieved on: 
Monday, August 16, 2021
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, European Association for the Study of the Liver, NUC, Trial of the century, Nuc, NASDAQ, RNA, U.S. Securities and Exchange Commission, Drug discovery, Glecaprevir/pibrentasvir, Blood, Child, Membrane protein, Fatty liver disease, RSV, EASL, Human, Patent, Respiratory syncytial virus, Degenerative disease, Hepatitis B, COVID-19, NASH, Pharmacokinetics, Research, Marketing, Security (finance), AbbVie, Recycling, Patient, Hepatocyte, Medication, Risk, Association, Conditional sentence, Severe acute respiratory syndrome coronavirus 2, Institute of Liver and Biliary Sciences, Transcriptome, Hepatitis B virus, Safety, AAV, Industry, HCV, HBV, Vaccine, Pharmaceutical industry, Hepatitis B Virus, Enanta, HEPATITIS B VIRUS, ENANTA

We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical study of EDP-721, an orally administered HBV RNA destabilizer that has the potential to reduce S antigen.

Key Points: 
  • We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical study of EDP-721, an orally administered HBV RNA destabilizer that has the potential to reduce S antigen.
  • The current standard of care for chronic HBV involves nucleoside reverse transcriptase inhibitors, or NUCs, which can suppress HBV replication.
  • This two-part Phase 1a/b study will initially evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in single and multiple ascending oral doses in healthy volunteers.
  • Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and SARS-CoV-2 (COVID-19).